BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 12883182)

  • 21. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal cancer treatment with low levels of mixed chimerism induced by nonmyeloablative regimen using cyclophosphamide in mice.
    Harano M; Eto M; Iwai T; Tatsugami K; Kiyoshima K; Kamiryo Y; Tsuneyoshi M; Yoshikai Y; Naito S
    Cancer Res; 2005 Nov; 65(21):10032-40. PubMed ID: 16267029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumor.
    Eto M; Kamiryo Y; Takeuchi A; Harano M; Tatsugami K; Harada M; Kiyoshima K; Hamaguchi M; Teshima T; Tsuneyoshi M; Yoshikai Y; Naito S
    Clin Cancer Res; 2008 May; 14(9):2833-40. PubMed ID: 18451251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Second transplant from the same donor without conditioning for bone marrow aplasia after non-myeloablative hematopoietic stem cell transplantation for chronic myeloid leukemia].
    Ishikawa I; Miyamura K; Yamada M; Sasaki O; Harigae H; Kameoka J; Meguro K; Sasaki T
    Rinsho Ketsueki; 2005 Dec; 46(12):1288-92. PubMed ID: 16447801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
    Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
    Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mixed chimerism and graft failure following conditioning with the fludarabine and cyclophosphamide nonablative regimen; conversion to full donor chimerism.
    Jillella AP; Shafer D; Klumpp TR; Emmons RV; Mangan KF
    Am J Hematol; 2007 Jun; 82(6):419-26. PubMed ID: 17211845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow.
    Truitt RL; Atasoylu AA
    Bone Marrow Transplant; 1991 Jul; 8(1):51-8. PubMed ID: 1833016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem cell transplantation?
    Hirshfeld E; Weiss L; Kasir J; Zeira M; Slavin S; Shapira MY
    Bone Marrow Transplant; 2006 Sep; 38(5):359-64. PubMed ID: 16862165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
    Jones SC; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
    J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-NK cell treatment induces stable mixed chimerism in MHC-mismatched, T cell-depleted, nonmyeloablative bone marrow transplantation.
    Cho SG; Shuto Y; Soda Y; Nakazaki Y; Izawa K; Uchimaru K; Takahashi S; Tani K; Tojo A; Asano S
    Exp Hematol; 2004 Dec; 32(12):1246-54. PubMed ID: 15588949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention and treatment of graft-versus-host disease by down-regulation of anti-host reactivity with veto cells of host origin.
    Weiss L; Slavin S
    Bone Marrow Transplant; 1999 Jun; 23(11):1139-43. PubMed ID: 10382953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8(+) T-cell count on day + 14 as a predictor of acute graft-versus-host disease.
    Petersen SL; Madsen HO; Ryder LP; Svejgaard A; Masmas TN; Dickmeiss E; Heilmann C; Vindeløv LL
    Biol Blood Marrow Transplant; 2004 May; 10(5):337-46. PubMed ID: 15111933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect.
    Imado T; Iwasaki T; Kuroiwa T; Sano H; Hara H
    Transplantation; 2004 Feb; 77(3):391-8. PubMed ID: 14966413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Photochemical treatment of donor lymphocytes inhibited their ability to facilitate donor engraftment or increase donor chimerism after nonmyeloablative conditioning or establishment of mixed chimerism.
    Johnson BD; Taylor PA; Stankowski MC; Talib S; Hearst JE; Blazar BR
    Biol Blood Marrow Transplant; 2002; 8(11):581-7. PubMed ID: 12463476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of graft-versus-leukemia (GVL) effect without graft-versus-host disease (GVHD) by pretransplant donor treatment with immunomodulators.
    Morecki S; Yacovlev E; Gelfand Y; Shabat Y; Slavin S
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):406-15. PubMed ID: 19285627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Study on graft-versus-leukemia effects of donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation].
    Du B; Li D; Xu K
    Zhonghua Xue Ye Xue Za Zhi; 2001 Aug; 22(8):403-7. PubMed ID: 11718089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versus-leukemia responses in mice receiving allogeneic bone marrow transplants.
    Billiau AD; Fevery S; Rutgeerts O; Landuyt W; Waer M
    Blood; 2002 Sep; 100(5):1894-902. PubMed ID: 12176914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.
    Spitzer TR; McAfee S; Sackstein R; Colby C; Toh HC; Multani P; Saidman S; Weyouth DW; Preffer F; Poliquin C; Foley A; Cox B; Andrews D; Sachs DH; Sykes M
    Biol Blood Marrow Transplant; 2000; 6(3A):309-20. PubMed ID: 10905768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.